Why Real-World Evidence Matters
National Pharmaceutical Council Director of Comparative Effectiveness Research Dr. Jennifer Graff explains the concept of real-world evidence (what works best in the real world under usual care settings), why it matters to health care decision-makers, and some of the barriers to the adoption of its use. She explains several ways to overcome these barriers, including increasing accessibility of the data, designing studies with the end-user in mind, enhancing the quality and transparency of the data, and evaluating the results.
For more information, visit http://www.npcnow.org/issue/real-world-evidence.
Видео Why Real-World Evidence Matters канала npcnow
For more information, visit http://www.npcnow.org/issue/real-world-evidence.
Видео Why Real-World Evidence Matters канала npcnow
Показать
Комментарии отсутствуют
Информация о видео
Другие видео канала
![Risk-Sharing Agreements in the US: Trends, Barriers and Prospects](https://i.ytimg.com/vi/vVLFNNWaEOQ/default.jpg)
![CER, Heterogeneity, and Cost Considerations](https://i.ytimg.com/vi/xwP4G7WQ5H0/default.jpg)
![NPC Webinar: Findings from Annual Survey of Health Care Stakeholders](https://i.ytimg.com/vi/ai_flOJ7LKk/default.jpg)
![Factors Affecting Patient Responses to Therapies](https://i.ytimg.com/vi/2Caa8BmeBEI/default.jpg)
![Current Challenges in Comparative Effectiveness Research](https://i.ytimg.com/vi/E7yZTRqbZb8/default.jpg)
![Individual Treatment Effects and Randomized Controlled Trials](https://i.ytimg.com/vi/Mtei0RjLtBs/default.jpg)
![Accountable Care Measures for High-Cost Specialty Care and Innovative Treatment](https://i.ytimg.com/vi/WZK68sft-Vw/default.jpg)
![FDA's Dr Temple: How Could the Pharma Industry Respond to CER Findings?](https://i.ytimg.com/vi/xcgUgdvevpo/default.jpg)
![FDA Use of Big Data in Modeling and Simulations](https://i.ytimg.com/vi/jBxm1qU8nVw/default.jpg)
![The Evidence Needs of Payers](https://i.ytimg.com/vi/eEBV458_qZ4/default.jpg)
![Anthem's Dr. Malin on Care Pathways: Their Implementation and Evaluation](https://i.ytimg.com/vi/qvFkCGlfVvw/default.jpg)
![Understanding the Concept of Heterogeneity](https://i.ytimg.com/vi/eKGBvB7r5nI/default.jpg)
![How Do Payers Consider and Value Evidence in Decision-Making?](https://i.ytimg.com/vi/2cJvXUrrOPU/default.jpg)
![Achieving Quality in Accountable Care Organizations](https://i.ytimg.com/vi/jpJa-nFo2Iw/default.jpg)
![Kimberly Westrich, MA, Vice President for Health Services Research, National Pharmaceutical Council](https://i.ytimg.com/vi/bYZvf56x-eU/default.jpg)
![Shifting the Focus From "How Much" to "How Well" We Spend Our Health Care Dollars](https://i.ytimg.com/vi/jYynaj4wa1c/default.jpg)
![CMS' High-Value Principles on Quality Measures](https://i.ytimg.com/vi/Zi2eR-_mDA8/default.jpg)
![Getting Patients Engaged in Comparative Effectiveness Research](https://i.ytimg.com/vi/3GUhQZgO9JU/default.jpg)
![FDA Moving Data to the Cloud, Data Mining Social Media](https://i.ytimg.com/vi/qmCGLFgAdXc/default.jpg)
![A Pharmaceutical Industry View on Standards to Govern Communication](https://i.ytimg.com/vi/V6gTIrFhbFo/default.jpg)